Physician profile
Prima Ray
NPI 1083270912
$5,657.27
in general payments reported to CMS, 2019-2025
36 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $1,006 · 2023: $1,171 · 2024: $1,686 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,163.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $679.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $595.27 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $453.49 | 2023-2025 | |
| Axonics, INC. | $451.44 | 2022 | |
| Exact Sciences Corporation | $428.34 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $413.89 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Coloplast Corp | $355.83 | 2021-2022 | |
| Novo Nordisk INC | $350.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $261.46 | 2021-2022 | |
| Astellas Pharma US INC | $227.47 | 2021-2024 | Veozah |
| Amgen INC. | $222.27 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $217.08 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $154.76 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $144.07 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.38 | 2023-2025 | Trintellix |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prima Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.